NEW YORK, Jan. 8, 2012 /CNW/ - Emo Capital Corp (OTCBB:EMOE.OB) announced today that it has obtained approval from the Financial Industry Regulatory Authority (FINRA) to change its trading symbol from "EMOE" to "NUVI" effective Monday January 9th, 2012.
The symbol change is another key step in the Company's strategy to rebrand its corporate identity through its wholly owned subsidiary NuVitality Labs. NuVitality Labs is a direct marketing corporation specializing in health and wellness categories.
Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend", "dramatically" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Emo Capital's filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to the ability of the company to control product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Emo Capitals's website does not constitute a part of this release.
For further information:
Phone: (888) 374-2961